Cancer News
  • Home
  • About
Sign in Subscribe

Dan Manning

Dan Manning
Probiotic-derived enzyme selectively kills colon cancer cells with extremely low effective dose.

colorectal-cancer

Probiotic-derived enzyme selectively kills colon cancer cells with extremely low effective dose.

Arginine deiminase (ADI) depletes arginine—an amino acid many cancer cells cannot synthesize themselves. This study tested a recombinant ADI from the probiotic bacterium Limosilactobacillus reuteri against HCT116 colorectal cancer cells.

By Dan Manning 13 Apr 2026
Delayed diagnosis of MEN2B in children with this distinctive syndrome leads to metastatic thyroid cancer at presentation.

thyroid-cancer

Delayed diagnosis of MEN2B in children with this distinctive syndrome leads to metastatic thyroid cancer at presentation.

MEN2B is a genetic syndrome caused by the RET p.M918T mutation requiring prophylactic thyroidectomy within the first year of life. This single-center study of 6 children with sporadic MEN2B found that despite exhibiting the complete, distinctive phenotype (marfanoid habitus, mucosal neuromas,…

By Dan Manning 13 Apr 2026
Nationwide radon atlas accurately predicts lung cancer risk in Northern Ireland—supports expanded screening.

lung-cancer

Nationwide radon atlas accurately predicts lung cancer risk in Northern Ireland—supports expanded screening.

This population-based case-control study from Northern Ireland is the first UK study to link a nationwide indicative radon atlas with lung cancer risk. 1,687 lung cancer cases (2006, 2014) were compared to 8,094 controls, with radon exposure classified by an atlas categorizing 1 km² areas.

By Dan Manning 13 Apr 2026
Engineering CAR-T cells to stay in bone marrow dramatically improves leukemia killing.

blood-cancer

Engineering CAR-T cells to stay in bone marrow dramatically improves leukemia killing.

The bone marrow microenvironment protects leukemia cells from both chemotherapy and immunotherapy, inhibiting T cell infiltration. This study addressed this by engineering CD33-targeted CAR-T cells to express constitutively active Rac1 (Rac1V12)—a GTPase that controls cell migration and tissue…

By Dan Manning 13 Apr 2026
Living in a high-radon zone raises ovarian cancer risk by 31%—the first study of its kind.

ovarian-cancer

Living in a high-radon zone raises ovarian cancer risk by 31%—the first study of its kind.

Few environmental risk factors for ovarian cancer are known. This prospective study of 127,547 postmenopausal women in the Women's Health Initiative followed participants for up to 31 years, linking residential radon zone data to ovarian cancer incidence and mortality.

By Dan Manning 13 Apr 2026
Living in poverty drives colorectal cancer deaths—and three factors explain why.

colorectal-cancer

Living in poverty drives colorectal cancer deaths—and three factors explain why.

People living in persistent poverty areas—where 20%+ have been poor for 30+ years—have higher colorectal cancer mortality. This large study of 5,028 Arkansas CRC patients linked registry, death certificate, and insurance claims data to identify what specifically drives this disparity.

By Dan Manning 13 Apr 2026
Migrant children with leukemia arriving in Argentina have dramatically lower survival than local patients.

blood-cancer

Migrant children with leukemia arriving in Argentina have dramatically lower survival than local patients.

Pediatric ALL survival rates are 80% in Argentina but below 60% in neighboring Paraguay, Peru, and Bolivia—driving medical migration. This retrospective study of 106 migrant children with ALL at a major Argentine center found stark disparities.

By Dan Manning 13 Apr 2026
Simple ratio of two blood test values predicts survival in metastatic colorectal cancer patients.

colorectal-cancer

Simple ratio of two blood test values predicts survival in metastatic colorectal cancer patients.

CA19-9/albumin ratio (cutoff 5.81) independently predicted shorter PFS (9.6 vs. 16.1 months) and OS (23.3 vs. 32.6 months) in 178 de novo mCRC patients starting standard chemotherapy + biologics. The ratio simultaneously reflects tumor burden (CA19-9) and host nutritional status (albumin), both…

By Dan Manning 13 Apr 2026
Ferroptosis regulators in glioma identified as potential drug targets using bioinformatics.

brain-cancer

Ferroptosis regulators in glioma identified as potential drug targets using bioinformatics.

Using GEO database gene expression profiles and the FerrDb ferroptosis gene database, 10 hub genes were identified in glioma: TP53, RRM2, EZH2, CDKN1A, MYCN, KIF20A, BLM, GLS2, HMOX1, and GOT1. Ferroptosis linked to p53 signaling, apoptosis, and immune regulation. Molecular docking confirmed good…

By Dan Manning 13 Apr 2026
Early structured psychological support after breast cancer surgery doubles medication adherence rates.

breast-cancer

Early structured psychological support after breast cancer surgery doubles medication adherence rates.

Retrospective Chinese study of 318 women with stage I-III HR+ breast cancer: early structured psychological care (≥3 sessions within 3 months of surgery) was associated with significantly better 1-year endocrine therapy adherence (OR 2.15) vs. no/minimal care. Good adherence: 77% (early structured)…

By Dan Manning 13 Apr 2026
Gastric cancer is declining globally but colorectal cancer is rising—especially in wealthier countries.

colorectal-cancer

Gastric cancer is declining globally but colorectal cancer is rising—especially in wealthier countries.

GBD 2021 data analysis (1990-2021, 204 countries) found gastric cancer ASIR and ASMR declined globally, especially in high-SDI countries. Colorectal cancer showed rising ASIR and prevalence but declining ASMR. Males had higher burden for both. Projections suggest gastric cancer to continue…

By Dan Manning 13 Apr 2026
Study identifies how BRCA-mutant breast cancer builds resistance to PARP inhibitors—and how to overcome it.

breast-cancer

Study identifies how BRCA-mutant breast cancer builds resistance to PARP inhibitors—and how to overcome it.

Patient samples from a Phase II neoadjuvant talazoparib trial (NCT03499353) revealed two resistance mechanisms: (1) BRN2 overexpression activating ATR/RAD51 and STAT3 pathways to restore HR repair (reversible with ATR and STAT3 inhibitors); (2) pre-existing SHLD2-deficient tumor subclone expansion.…

By Dan Manning 13 Apr 2026
See all
Cancer News
  • Sign up
Powered by Ghost

Cancer News

AI-powered cancer research digest and ideas, published daily